search
Back to results

Expanded Access for KHK2455

Primary Purpose

Glioblastoma Multiforme

Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
KHK2455
Sponsored by
Kyowa Kirin, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Glioblastoma Multiforme

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)

Inclusion Criteria:

-

Exclusion Criteria:

-

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    January 21, 2020
    Last Updated
    August 9, 2021
    Sponsor
    Kyowa Kirin, Inc.
    Collaborators
    University of New Mexico Cancer Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04321694
    Brief Title
    Expanded Access for KHK2455
    Official Title
    Expanded Access for KHK2455
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    March 2020
    Overall Recruitment Status
    No longer available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Kyowa Kirin, Inc.
    Collaborators
    University of New Mexico Cancer Center

    4. Oversight

    5. Study Description

    Brief Summary
    This is an expanded access program for eligible participants. This program is designed to provide access to KHK2455 in combination with Mogamulizumab prior to the approval by the local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving this investigational therapy based on the individual patients medical history and eligibility criteria.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Glioblastoma Multiforme

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    KHK2455
    Other Intervention Name(s)
    Mogamulizumab

    10. Eligibility

    Eligibility Criteria
    Inclusion Criteria: - Exclusion Criteria: -

    12. IPD Sharing Statement

    Learn more about this trial

    Expanded Access for KHK2455

    We'll reach out to this number within 24 hrs